Venom and Biotherapeutics Molecules Laboratory, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Student Research Committee, Pasteur Institute of Iran, Tehran, Iran.
PLoS One. 2022 Feb 25;17(2):e0264353. doi: 10.1371/journal.pone.0264353. eCollection 2022.
Although high-dose IL-2 has clear antitumor effects, severe side effects like severe toxicity and activation of Tregs by binding of IL-2 to high-affinity IL-2R, hypotension, and vascular leak syndrome limit its applications as a therapeutic antitumor agent. Here in this study, a rational computational approach was employed to develop and design novel triple-mutant IL-2 variants with the aim of improving IL-2-based immunotherapy. The affinity of the mutants towards IL-2Rα was further computed with the aid of molecular dynamic simulations and umbrella sampling techniques and the obtained results were compared to those of wild-type IL-2. In vitro experiments by flow cytometry showed that the anti-CD25 mAb was able to bind to PBMC cells even after mutant 2 preincubation, however, the binding strength of the mutant to α-subunit was less than of wtIL-2. Additionally, reduction of IL-2Rα subunit affinity did not significantly disturb IL-2/IL2Rβγc subunits interactions.
虽然高剂量的白细胞介素 2(IL-2)具有明显的抗肿瘤作用,但严重的副作用,如严重的毒性和 Tregs 的激活(通过 IL-2 与高亲和力的 IL-2R 的结合)、低血压和血管渗漏综合征,限制了其作为治疗性抗肿瘤药物的应用。在本研究中,采用合理的计算方法来开发和设计新型三突变白细胞介素 2 变体,旨在改善基于白细胞介素 2 的免疫治疗。进一步借助分子动力学模拟和伞状采样技术计算了突变体与 IL-2Rα的亲和力,将得到的结果与野生型白细胞介素 2 进行比较。流式细胞术的体外实验表明,抗 CD25 mAb 甚至在突变体 2 预孵育后仍能与 PBMC 细胞结合,但突变体与 α-亚基的结合强度低于 wtIL-2。此外,降低 IL-2Rα 亚基的亲和力不会显著干扰 IL-2/IL2Rβγc 亚基的相互作用。